Skip to content

Protocol Deviations: A Holistic Approach from Defining to Reporting

Defining and processing protocol deviations (PD) can be complex and varied, and present challenges for several stakeholders within the clinical trial ecosystem.  Improvements in protocol deviation management, and reporting processes can aid those conducting clinical research in a variety of ways including: rapid identification of important protocol deviations and assessing potential or real impact of COVID-19 on their specific study.

To address various challenges, TransCelerate’s Protocol Deviations (PD) Initiative team recently published an article, “Protocol Deviations: A Holistic Approach from Defining to Reporting.”  The publication identifies key principles to build upon and clarify the definition of a protocol deviation and describes a holistic approach to their management. These approaches are adapted to suit a variety of indications, study designs, and investigational agents while supporting consistent application within a study, program, or organization.

This paper further bolsters TransCelerate’s Protocol Deviations Toolkit and delves into the various solutions that the Protocol Deviations Initiative has developed and help outline an end-to-end process flow.

I hope you enjoy reading the paper and find the step-by-step guide on the Protocol Deviations solution page useful.

Laura is the co-lead of the Protocol Deviations Workstream and is Director, Global Clinical Trial Operations at Merck & Co., Inc. She is a member of TransCelerate BioPharma’s Oversight Committee. This Committee is the governing body for decisions related to the clinical portion of the portfolio, including project sponsorship. Laura draws on her experience as an Operations Director for a busy therapeutic area and as head of a performance and analytics group to provide this perspective. Internally, she has responsibility for driving engagement, and facilitating adoption or internalization of TransCelerate solutions in alignment with Merck’s objectives. Additionally, she watches for opportunities to match innovative approaches to process improvement initiatives or other areas of focus.  

Related Blog Posts

Collaboration in Times of Crisis

In early February, TransCelerate had a highly engaging Annual Meeting with FDA colleagues to discuss our 2020 plans and look for promising ways to accelerate and evolve new areas of clinical research. By early March, the entire world—our industry included—went into shock as COVID-19 travelled the globe, hitting humanity in extraordinary ways. 2020 has impacted…

Clinical Study Reports for Studies Impacted by COVID-19: Key Considerations

Like many features of our personal and professional lives, the COVID-19 pandemic has had a significant impact on clinical research, especially on active treatment studies. From increased difficulty enrolling participants in studies and collecting measurements to reduced availability of supplies and potential new biases in the data, clinical research is grappling with major changes and…

Inspiring Inclusion: The Power of Pivotal Moments 

This year, TransCelerate honored International Women’s Day, and the theme of “inspiring inclusivity” by gathering a panel of distinguished thought leaders within biopharma R&D for a discussion on “Inspiring Inclusion: The Power of Pivotal Moments.”  TransCelerate COO Allison Cuff Shimooka moderated the event. Panelists were Esther Krofah (Milken Institute Health), Joni Rutter (NCATS/NIH), Janet Woodcock…